2cureX AB
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
2CUREX | ST
Overview
Corporate Details
- ISIN(s):
- SE0010468124
- LEI:
- 549300SFOL75WIYF2O80
- Country:
- Sweden
- Address:
- Box 159, 261 22 Landskrona
- Website:
- https://www.2curex.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
2cureX AB is a biotechnology company specializing in precision oncology through functional drug sensitivity testing. The company develops and commercializes the IndiTreat® family of tests, its core product line. IndiTreat® is the first CE-marked in-vitro diagnostic (IVD) test that utilizes patient-derived 3D tumoroids to predict individual responses to cancer treatments. This technology provides oncologists with personalized data to guide therapy selection, particularly for patients with metastatic colorectal cancer. The company's mission is to improve cancer treatment outcomes by matching specific therapies to individual patients, thereby enhancing the efficacy of oncological care.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all 2cureX AB filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for 2cureX AB
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for 2cureX AB via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
/other/Diamyd_Medical_AB_publ-logo.png){kind=logo}
